Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET)
Macrovascular disease is the major cause of mortality in persons with type 2 diabetes mellitus, and hypertension is an important factor contributing to this high prevalence. High blood pressure is about twice as common in persons with diabetes mellitus as in those without. Up to 75% of diabetes-related cardiovascular complications are attributed to hypertension. These observations are part of the rationale for recommendations for more aggressive lowering of blood pressure (to < 130/85 mm Hg) in persons with coexistent diabetes and hypertension. This may require therapy with a combination of antihypertensive agents. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET), discussed herein, supports the case for combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist in diabetic patients with hypertension.
Sowers
J R
JR
Division of Endocrinology, Metabolism and Hypertension, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
D017311:Amlodipine / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015986:Confounding Factors, Epidemiologic; D048909:Diabetes Complications; D017328:Fosinopril / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000628:therapy; D008019:Life Style; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017311:Amlodipine; D017328:Fosinopril